Cargando…

The UK SPIRIT 1 trial in newly-diagnosed chronic myeloid leukaemia (CML)

Detalles Bibliográficos
Autores principales:	Gallipoli, Paolo, Clark, Richard E, Byrne, Jenny, Apperley, Jane F, Milojkovic, Dragana, Foroni, Letizia, Goldman, John M, O’Brien, Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7613110/ https://www.ncbi.nlm.nih.gov/pubmed/34993961 http://dx.doi.org/10.1111/bjh.17961

Ejemplares similares

Molecular techniques for the personalised management of patients with chronic myeloid leukaemia
por: Alikian, Mary, et al.
Publicado: (2017)

Consensus on BCR‐ABL1 reporting in chronic myeloid leukaemia in the UK
por: Cross, Nicholas C. P., et al.
Publicado: (2018)

MR4 sustained for 12 months is associated with stable deep molecular responses in chronic myeloid leukemia
por: Claudiani, Simone, et al.
Publicado: (2019)

FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions
por: May, Philippa C., et al.
Publicado: (2023)

Diagnostic radiography as a risk factor for chronic myeloid and monocytic leukaemia (CML).
por: Preston-Martin, S., et al.
Publicado: (1989)

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease
por: Horne, G. A., et al.
Publicado: (2020)

Serotonin re-uptake transporter gene polymorphisms are associated with imatinib-induced diarrhoea in chronic myeloid leukaemia patients
por: Davies, Andrea, et al.
Publicado: (2020)

An investigation of the use of app technology to support clinical management of patients with chronic myeloid leukaemia (CML)
por: Khadam, Saffiya, et al.
Publicado: (2022)

PB1973: MOLECULAR PATTERNS OF RESPONSE AFTER FRONTLINE TREATMENT IN CHRONIC MYELOID LEUKAEMIA (CML).
por: Fernandez-Leyva, Harberth
Publicado: (2023)

Lymphoid blast crisis after prolonged treatment‐free remission in chronic myeloid leukaemia after tyrosine kinase inhibitor de‐escalation during the COVID‐19 pandemic
por: Avenoso, Daniele, et al.
Publicado: (2021)

A retrospective observational research study to describe the real‐world use of bosutinib in patients with chronic myeloid leukemia in the United Kingdom and the Netherlands
por: Claudiani, Simone, et al.
Publicado: (2022)

Cross-talk between Bcr-abl and the Thioredoxin System in Chronic Myeloid Leukaemia: Implications for CML Treatment
por: Clapper, Erin, et al.
Publicado: (2020)

Prevalence of Sars-Cov-2 Infection in Patients with Chronic Myeloid Leukemia
por: Claudiani, Simone, et al.
Publicado: (2020)

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006)
por: Hjorth-Hansen, Henrik, et al.
Publicado: (2015)

Co‐diagnoses of acute myeloid leukaemia and COVID‐19: presentation and management implications
por: O'Brien, Amy, et al.
Publicado: (2020)

The development of dasatinib as a treatment for chronic myeloid leukemia (CML): from initial studies to application in newly diagnosed patients
por: Hochhaus, Andreas, et al.
Publicado: (2013)

Multidrug resistance in chronic myeloid leukaemia: how much can we learn from MDR–CML cell lines?
por: Rumjanek, Vivian M., et al.
Publicado: (2013)

Rarity of microsatellite alterations in acute myeloid leukaemia.
por: Sill, H., et al.
Publicado: (1996)

The Prognostic Significance of C-Reactive Protein to Albumin Ratio in Newly Diagnosed Acute Myeloid Leukaemia Patients
por: Dou, Liurui, et al.
Publicado: (2022)

Psychological Factors Affecting the Willingness to Accept a Possible Tyrosine Kinase Inhibitor (TKI) Discontinuation in Chronic Myeloid Leukaemia (CML) Patients
por: Cutica, Ilaria, et al.
Publicado: (2022)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
por: Kreutzman, Anna, et al.
Publicado: (2019)

p53 status of newly established acute myeloid leukaemia cell lines
por: Zheng, A, et al.
Publicado: (1999)

Nilotinib dose‐optimization in newly diagnosed chronic myeloid leukaemia in chronic phase: final results from ENESTxtnd
por: Hughes, Timothy P., et al.
Publicado: (2017)

Somatic variants in epigenetic modifiers can predict failure of response to imatinib but not to second-generation tyrosine kinase inhibitors
por: Nteliopoulos, Georgios, et al.
Publicado: (2019)

Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial
por: Brümmendorf, Tim H., et al.
Publicado: (2022)

Bosutinib Versus Imatinib for Newly Diagnosed Chronic Myeloid Leukemia: Results From the Randomized BFORE Trial
por: Cortes, Jorge E., et al.
Publicado: (2018)

COVID-19 in Patients (pts) with Chronic Myeloid Leukemia (CML): Results from the International CML Foundation (iCMLf) CML and COVID-19 (CANDID) Study
por: Rea, Delphine, et al.
Publicado: (2020)

Polypharmacy-Induced Long QT Syndrome in a Patient With Newly Diagnosed Acute Myeloid Leukaemia: A Case Report
por: Khan, Zahid
Publicado: (2023)

Childhood leukaemia and lymphoma: African experience supports a role for environmental factors in leukaemogenesis
por: Williams, Christopher KO, et al.
Publicado: (2014)

Moving on up: Second-Line Agents as Initial Treatment for Newly-Diagnosed Patients with Chronic Phase CML
por: Shieh, Marie P., et al.
Publicado: (2011)

Impact of emerging ACA on survival in chronic myeloid leukemia (CML)
por: Hehlmann, Rüdiger, et al.
Publicado: (2022)

Validation of CIP2A as a Biomarker of Subsequent Disease Progression and Treatment Failure in Chronic Myeloid Leukaemia
por: Clark, Richard E., et al.
Publicado: (2021)

Recurrent histone mutations in T‐cell acute lymphoblastic leukaemia
por: Collord, Grace, et al.
Publicado: (2018)

Chemotherapy of the Myeloid Leukaemias
por: Stuart, John
Publicado: (1980)

The incidence of atypical patterns of BCR-ABL1 rearrangement and molecular-cytogenetic response to tyrosine kinase inhibitor therapy in newly diagnosed cases with chronic myeloid leukemia (CML)
por: Švabek, Željka Tkalčić, et al.
Publicado: (2018)

European LeukemiaNet recommendations for the management and avoidance of adverse events of treatment in chronic myeloid leukaemia
por: Steegmann, J L, et al.
Publicado: (2016)

Sorafenib or placebo in patients with newly diagnosed acute myeloid leukaemia: long-term follow-up of the randomized controlled SORAML trial
por: Röllig, Christoph, et al.
Publicado: (2021)

The trace that is valuable: serum copper and copper to zinc ratio for survival prediction in younger patients with newly diagnosed acute myeloid leukaemia
por: Li, Taotao, et al.
Publicado: (2023)

Cost Effectiveness of Gemtuzumab Ozogamicin in the First-Line Treatment of Acute Myeloid Leukaemia in the UK
por: Russell-Smith, T. Alexander, et al.
Publicado: (2021)

Genomic amplification of BCR/ABL1 and a region downstream of ABL1 in chronic myeloid leukaemia: a FISH mapping study of CML patients and cell lines
por: Virgili, Anna, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_grl3onc35n4516ma6cncupsvtg